This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Guangdong Taiantang Pharmaceutical Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Shaobin Ke

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	no data
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.2yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Shaobin Ke (45 yo)

no data

Amtszeit

CN¥1,680,000

Vergütung

Mr. Ke Shaobin serves as Chairman of the Board at Guangdong Taiantang Pharmaceutical Co., Ltd. and serves as its General Manager. He served as Vice Chairman of the Board of Directors at Goangdong Taiantang...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shaobin Ke	Chairman of the Board of Directors & GM	no data	CN¥1.68m	keine Daten
Xiang Yu	CFO & Non-Independent Director	no data	CN¥300.00k	keine Daten
Shao Ke	Managing Deputy GM & Non-Independent Director	5.2yrs	CN¥880.00k	3.18% CN¥ 6.6m
Xiu Song	Non-Independent Director	13.2yrs	CN¥96.00k	keine Daten
Qiu Hua Xu	Member of the Supervisory Board	no data	CN¥31.20k	keine Daten
Qing Hu	Non-Independent Director	no data	CN¥78.00k	keine Daten
Li Liu	Independent Director	5.2yrs	CN¥120.00k	keine Daten
Guihua Wang	Independent Director	5.2yrs	CN¥120.00k	keine Daten
Zhijin Nie	Independent Director	5.2yrs	CN¥120.00k	keine Daten
Wei Zhu	Independent Director	1.5yrs	keine Daten	keine Daten
Zhongxi Cai	Independent Director	1.5yrs	keine Daten	keine Daten
Yiyong Shen	Independent Director	1.5yrs	keine Daten	keine Daten

5.2yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrener Vorstand: 002433Die Vorstandsmitglieder gelten als erfahren (5.2 Jahre durchschnittliche Amtszeit).

This company listing is no longer active

Guangdong Taiantang Pharmaceutical Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Guangdong Taiantang Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Guangdong Taiantang Pharmaceutical Co., Ltd., Annual General Meeting, May 19, 2023

Guangdong Taiantang Pharmaceutical Co., Ltd. Approves Board Elections

Insufficient new directors

Guangdong Taiantang Pharmaceutical Co., Ltd., Annual General Meeting, Jul 08, 2022

Insufficient new directors

Recent updates

Guangdong Taiantang Pharmaceutical Co., Ltd.(SZSE:002433) dropped from Shenzhen Stock Exchange A Share Index

First quarter 2024 earnings released: CN¥0.07 loss per share (vs CN¥0.08 loss in 1Q 2023)

Guangdong Taiantang Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

New minor risk - Market cap size

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024

Third quarter 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.45 loss in 3Q 2022)

New major risk - Share price stability

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Second quarter 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.099 loss in 2Q 2022)

Guangdong Taiantang Pharmaceutical Co., Ltd., Annual General Meeting, May 19, 2023

First quarter 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.05 loss in 1Q 2022)

Guangdong Taiantang Pharmaceutical Co., Ltd. Approves Board Elections

Insufficient new directors

Third quarter 2022 earnings released: CN¥0.041 loss per share (vs CN¥0.043 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.099 loss per share (vs CN¥0.73 profit in 2Q 2021)

Guangdong Taiantang Pharmaceutical Co., Ltd., Annual General Meeting, Jul 08, 2022

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.08 loss in 1Q 2021)

Insufficient new directors

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on Jun 16, 2022

High number of new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.043 (vs CN¥0.02 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.73 (vs CN¥0.011 in 2Q 2020)

Chengdu Yiyun Technology Co., Ltd. completed the acquisition of a 47.35% stake in Guangdong Kangaiduo Digital Health Technology Co., Ltd. from Guangdong Taiantang Pharmaceutical Co., Ltd. (SZSE:002433).

First quarter 2021 earnings released: CN¥0.08 loss per share (vs CN¥0.02 profit in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.03 (vs CN¥0.13 in FY 2019)

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥3.49

New 90-day low: CN¥4.02

New 90-day low: CN¥4.41

New 90-day low: CN¥4.53

Third quarter earnings released

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

Guangdong Taiantang Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter